ALSO IN THIS MONTH'S ISSUE

• The Bipartisan Dismemberment Of The ACA

  Hours after the House of Representatives impeached President Donald J. Trump, it passed a gargantuan omnibus appropriation package costing $1.4 trillion in 2020 that continues the bipartisan unravelling of the Affordable Care Act (i.e., Obamacare) by repealing three taxes critical to its financing: the “Cadillac tax” on high-cost insurance plans, the medical device excise tax, and the health insurance tax. Together, their repeal costs the federal government $373.3 billion in lost revenue over the next 10 years according to the Joint Committee on Taxation.

• Women On Boards: How We Get From Here To There

  Even though females have “arrived” as biotech executives, there’s more to be done: serving as CEOs, advisors, and directors to help companies achieve their missions.

• A Small Biopharma That Doesn’t Use CROs

  When it comes to conducting clinical trials, most emerging companies choose to access external resources through partnering with CROs. That is what makes Martin Lehr, CEO of Context Therapeutics different. He prefers to bypass CROs and take part in Investigator-Sponsored Trials (ISTs).

• How Biopharma Leaders Can Ward Off A Perfect Storm: Part 2

  If you’re a senior biopharma executive, your best industry bet is to incorporate compliance into your highest-level strategic planning as early as possible. Doing so will ultimately benefit the company, come rain or shine.

• How To Overcome The Challenge Of Valuing A Biotech

  Because of the unknowns around revenue streams, biotech valuation may appear to be more guesswork than science. However, common valuation methods can help account for some of the product-line uncertainty.